Biomarkers associated with response to regorafenib in patients with hepatocellular carcinoma.
Gastroenterology 2019 02 06() pii 10.1053/j.gastro.2019.01.261 Abstract BACKGROUND & AIMS In a phase 3 trial (RESORCE), regorafenib increased overall survival compared with placebo in patients with hepatocellular carcinoma...
Read More